Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitiligo and the Koebner phenomenon
2009-017425-19Phase 2Completed
- Sponsor
- Ghent University Hospital
- Start
- Dec 2009
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of mometasone, tacrolimus and pimecrolimus in Vitiligo (3 arms), sponsored by Ghent University Hospital. Primary endpoint: clinical evaluation on different time points. Started Dec 2009; status: completed.
02
Drugs
mometasonetacrolimuspimecrolimus
03
Conditions
Vitiligo
Beyond the preview
Go deeper on 2009-017425-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017425-19.